Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kane BiotechKNBIF Revenue per Share is $0.00 as of Mar. 2026. The stock has 6 warning signs investors should review. Among 769 Biotechnology companies, Kane Biotech ranks better than 82.57% on this metric.
Kane Biotech's revenue per share for the
three
months ended in Mar. 2026 was $0.00.
Kane Biotech's revenue per share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00.
Warning Sign:
Kane Biotech Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Kane Biotech was -100.00% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 44.20% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was -18.50% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was -9.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Kane Biotech's Revenue per Share or its related term are showing as below:
KNBIF'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -63.8 Med: 6.3 Max: 51.8
Current: 44.2
During the past 13 years, Kane Biotech's highest 3-Year average Revenue Per Share Growth Rate was 51.80% per year. The lowest was -63.80% per year. And the median was 6.30% per year.
KNBIF's 3-Year Revenue Growth Rate is ranked better than 82.57% of 769
companies
in the Biotechnology industry
Industry Median: 3.1
vs KNBIF: 44.20
Kane Biotech (OTCPK:KNBIF) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Kane Biotech Revenue per Share Related Terms
Kane Biotech Revenue per Share Historical Data
* Premium members only.
The historical data trend for Kane Biotech's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KNBIF vs VRTX, REGN, ALNY: Revenue per Share Comparison
For the Biotechnology subindustry, Kane Biotech's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kane Biotech PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kane Biotech's PS Ratio distribution charts can be found below:
* The bar in red indicates where Kane Biotech's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Kane Biotech's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kane Biotech (KNBIF) has a Revenue per Share of $0.00 as of Mar. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Kane Biotech and its competitors. According to the industry distribution chart, Kane Biotech ranks #134 out of 769 companies in the Biotechnology industry, placing it in the top 17.4%.
Is Kane Biotech's Revenue per Share too high?
Kane Biotech's current Revenue per Share is $0.00. Based on the distribution chart, Kane Biotech ranks #134 out of 769 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Kane Biotech's Revenue per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kane Biotech ranks #134 out of 769 companies for Revenue per Share. This places Kane Biotech in the top 17% of its industry — outperforming the majority of peers. The industry median Revenue per Share is 3.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Biotechnology company?
The median Revenue per Share among Biotechnology companies is 3.10, based on 769 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Kane Biotech and its competitors. For the Biotechnology industry, the median Revenue per Share is 3.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kane Biotech's current Revenue per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kane Biotech stock overvalued right now?
Kane Biotech (KNBIF) has a current Revenue per Share of $0.00. The current Revenue per Share is $0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Kane Biotech (KNBIF), the current Revenue per Share is $0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The company's operating segments are animal health and human health. It derives maximum revenue from Animal health segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNBIF has been successfully added to your 
